Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Click Therapeutics, Inc.

http://clicktherapeutics.com/#main

Latest From Click Therapeutics, Inc.

Click Targets ‘Best-In-Class Digital Therapy For Chronic Weight Management’ With Better Therapeutics Acquisition

Click will fold Better Therapeutics’ FDA-cleared AspyreRx prescription digital therapeutic into R&D for its own CT-181, which promises to optimize obesity treatment in combination with drugs such as GLP-1s and provide "valuable real-world data insights for providers and payers." Better Therapeutics shuttered its operations in March, signaling continued challenges for digital medicine innovators.

M & A Innovation

Otsuka Progresses Digital Push With US Approval Of MDD App

Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.

Approvals Digital Health

News We're Watching: Abbott, Click, Otsuka, Prenosis Win FDA Approval; EU Health Data Space Proposal, And More

This week, Abbott, Click and Otsuka, Prenosis won the FDA nod respectively for an in vitro diagnostic to evaluate patients for concussion, the first prescription digital therapeutic to treat major depressive disorder and a software to predict sepsis. Also on the regulatory front, the FDA will now take 513(g)s forms via its eSTAR framework. In Europe, the debate of what personal information can be shared continues. 

News We're Watching Approvals

Boehringer Marches On In Mental Health With Sosei Heptares Pact

The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.

Deals Neurology
See All

Company Information

  • Industry
  • Digital Health
  • Pharmaceuticals
  • Services
  • Medical Devices
    • Monitoring Equipment & Devices
UsernamePublicRestriction

Register